• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Precision Medicine Oncology | Molecular Profiling | News, Analysis, Insights

Culmination Bio, BillionToOne Partner to Validate Cancer Diagnostics

by Syed Hamza Sohail 04/04/2024 Leave a Comment

Culmination Bio, BillionToOne Partner to Validate Cancer Diagnostics

What You Should Know: Culmination Bio, a data and technology company combining clinical and biospecimen data, announced a partnership with BillionToOne, Inc., a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all.Culmination Bio and BillionToOne are working together to leverage their respective strengths in order to facilitate the development and validation of robust and impactful oncology
Read More

C2i Genomics & AstraZeneca Partner to Advance Cancer Therapy

by Syed Hamza Sohail 01/05/2023 Leave a Comment

C2i Genomics & AstraZeneca Team Up to Advance Cancer Therapy

What You Should Know: - C2i Genomics, a cancer intelligence company, today announced a strategic collaboration with AstraZeneca, a global life sciences and pharmaceutical leader.  - The two companies have collaborated to evaluate the potential of whole-genome minimal residual disease (MRD) testing across solid cancers. - Expanding on a completion of AstraZeneca’s accelerator BeyondBio SCALE program for start-ups and successful technology validation, C2i Genomics and AstraZeneca
Read More

OncoHost Raises $35M for AI-Powered Precision Oncology Platform

by Fred Pennic 05/10/2022 Leave a Comment

OncoHost Raises $35M for AI-Powered Precision Oncology Platform

What You Should Know: - OncoHost, an AI-powered precision oncology platform, today announced a $35M Series C funding round led by ALIVE Israel HealthTech VC, as well as other prominent investors. Additional investors included leading Israeli financial firm Leumi Partners, Israel’s largest pension fund Menora Mivtachim, OurCrowd and other existing investors. - The funding will go towards expanding OncoHost’s ongoing multicenter PROPHETIC trial as well as support its upcoming
Read More

Mayo Clinic Partners with VUNO to Develop AI-Driven Precision Oncology Solutions

by Fred Pennic 04/22/2022 Leave a Comment

Mayo Clinic Partners with VUNO to Develop AI-Driven Precision Oncology Solutions

What You Should Know: - Mayo Clinic has signed a research agreement with VUNO, a global medical artificial intelligence (AI) company to develop advanced AI-driven precision oncology solutions to deliver precision oncology care. - Through this research agreement, VUNO will establish a collaboration with Mayo Clinic to develop innovative AI and machine learning solutions for more precise diagnosis, prognosis and treatment stratification in cancer. - This collaborative agreement combines
Read More

Syapse, Pfizer Extends Collaboration to Generate Real-World Evidence in Breast Cancer

by Jasmine Pennic 01/20/2022 Leave a Comment

FDA, Syapse Expand Research to Generate Real-World Data Related to COVID-19 and Cancer

What You Should Know: - Syapse, a real-world evidence company that informs cancer care, announced that it will extend its collaboration with Pfizer to generate real-world evidence in breast cancer. - This is the third phase of the collaboration, which was first announced in 2019 and renewed in 2021. Generate Real-World Evidence in Breast Cancer As part of the next phase of the collaboration, Syapse will provide insights and services to Pfizer, using the Syapse Learning Health Network
Read More

Notable Labs Launches by Acquiring Rights to Volasertib – Will Use Data, AI to Fast-Track Cancer Treatment

by Fred Pennic 11/11/2021 Leave a Comment

What You Should Know: - Coming out of stealth, Notable Labs, a pioneer and developer of predictive precision medicines, is acquiring worldwide development and commercial rights to volasertib, a PLK-1 inhibitor in acute myeloid leukemia (AML) from Oncoheroes. - Notable will leverage its high-fidelity Predictive Precision Medicines Platform to identify and select volasertib-responsive patients prior to their treatment and fast-track volasertib’s clinical development
Read More

Cedars-Sinai Cancer Launches ‘Molecular Twin’ Initiative for Precision Cancer Treatment

by Jasmine Pennic 09/09/2021 Leave a Comment

Cedars-Sinai Cancer Launches ‘Molecular Twin’ Initiative to Advance Precision Cancer Treatment

What You Should Know: - Cedars-Sinai Cancer and Tempus, a provider of artificial intelligence and precision medicine, are harnessing the power of big data and AI to design personalized cancer treatment options by creating virtual replicas of patients' DNA, RNA, protein and other information to help identify the most effective approach to each individual's disease. - By creating these "molecular twins," scientists can genetically classify cancer genes and proteins of particular tumors
Read More

Foundation Medicine Integrates with Epic EMR for Genomic Insights for Precision Cancer Care

by Fred Pennic 08/26/2021 Leave a Comment

Foundation Medicine Integrates with Epic EMR for Genomic Insights for Precision Cancer Care

What You Should Know:  - Foundation Medicine (FMI) announced today a partnership to integrate its comprehensive genomic testing services into Epic’s electronic medical record (EMR) platform, making it easier for oncologists to order comprehensive genomic tests (CGP), review results, continually access clinical and genomic information and share among their care teams in order to develop personalized treatment plans quickly and efficiently for their patients. See the full release
Read More

AWS, PHDA Collaborate to Develop Breast Cancer Screening and Depression Machine Learning Models

by Fred Pennic 10/06/2020 Leave a Comment

AWS, PHDA Collaborate to Develop Breast Cancer Screening and Depression Machine Learning Models

What You Should Know: - Amazon Web Services (AWS) and the Pittsburgh Health Data Alliance (PHDA) announce a collaboration to produce more accurate machine learning models for breast cancer screening and depression. - In work funded through the PHDA-AWS collaboration, a research team led by Shandong Wu, an associate professor at the University of Pittsburgh Department of Radiology, is using deep-learning systems to analyze mammograms in order to predict the short‐term risk of developing
Read More

CancerIQ Raises $5M to Expand Genetic Cancer Risk Assessment Platform

by Fred Pennic 08/14/2020 Leave a Comment

CancerIQ Raises $5M to Expand Genetic Cancer Risk Assessment Platform

What You Should Know: - CancerIQ raises $5M in Series A funding led by HealthXVentures to accelerate the growth of its genetic cancer risk assessment platform to identify and manage patients at high risk of cancer. - CancerIQ’s technology enables hospitals to use genomics to personalize the prevention and early detection of cancer. - Two new hires recently joined CancerIQ’s newly formed Integrated Products team from Epic, with the goal of advancing CancerIQ’s integration with leading
Read More

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Next Page

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Kinetik CEO Sufian Chowdhury on Fighting NEMT Fraud & Waste

Most-Read

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

WeightWatchers Files for Bankruptcy to Eliminate $1.15B in Debt

WeightWatchers Files for Bankruptcy to Eliminate $1.15B in Debt

KLAS: Epic Dominates 2024 EHR Market Share Amid Focus on Vendor Partnership; Oracle Health Sees Losses Despite Tech Advances

KLAS: Epic Dominates 2024 EHR Market Share Amid Focus on Vendor Partnership; Oracle Health Sees Losses Despite Tech Advances

'Cranky Index' Reveals EHR Alert Frustration Peaks Midweek, Highest Among Admin Staff

‘Cranky Index’ Reveals EHR Alert Frustration Peaks Midweek, Highest Among Admin Staff

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |